Eddy Wu, Arctic Vision

Arc­tic Vi­sion col­lects $100M to bring US eye dis­ease can­di­dates over­seas

With three eye dis­ease can­di­dates, in-li­censed from the US, Shang­hai-based Arc­tic Vi­sion has hooked more than $100 mil­lion to see the ther­a­pies to the Chi­nese mar­ket — and pos­si­bly be­yond, if CEO Ed­dy Wu gets his way.

Wu took the wraps off a Se­ries B round Wednes­day evening, just sev­er­al months af­ter un­veil­ing a $32 mil­lion A round. The new funds will be used to de­vel­op three can­di­dates li­censed from Clear­side Bio­med­ical and Eye­n­ovia (one of which was slapped with a CRL back in 2019), and ex­tend the com­pa­ny’s reach to oth­er parts of Asia, he said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.